Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

NCT05740566 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05740566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05740566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 31, 2023
Completion date
March 26, 2028
Enrollment
509 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)